Shares of Jaguar Health Inc. JAGX were mauled for a 21.2% loss in morning trading Tuesday, after the drug maker said it has not yet received data supporting the Phase 3 trial of its treatment of diarrhea in cancer patients receiving therapy. The company is awaiting results from its Good Clinical Practice vendors supporting the trial. The results are “forthcoming,” the San Francisco-based company said. “The OnTarget trial is our paramount near-term clinical milestone,” said Chief Executive Lisa Conte. “We look forward to announcing and presenting the top line results when they are available.” Before Tuesday’s selloff,…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Already a subscriber?
Log In
